A new look at drugs targeting malignant melanoma--an application for mass spectrometry imaging.

摘要: Malignant melanoma (MM) patients are being treated with an increasing number of personalized medicine (PM) drugs, several which small molecule drugs developed to treat specific disease genotypes and phenotypes. In particular, the clinical application protein kinase inhibitors has been highly effective for certain subsets MM patients. Vemurafenib, a inhibitor targeting BRAF-mutated protein, shown significant efficacy in slowing progression. this paper, we provide overview new generation targeted demonstrate first data on localization PM within tumor compartments. study, have introduced MALDI-MS imaging information one currently used treatment MM, vemurafenib. proof-of-concept vitro was identify vemurafenib applied metastatic lymph nodes tumors subjects attending regional hospital network Southern Sweden. The paper provides evidence BRAF overexpression isolated from drug BRAF, vemurafenib, using MS fragment ion signatures. Our ability determine uptake at target sites directed therapy important opportunity our understanding about mode action activity environment.